134271-93-5

Basic information

• Product Name: 1-(3-nitrophenyl)-2-propylidenehydrazine
• Synonyms: 1-(3-nitrophenyl)-2-propylidenehydrazine
• CAS NO: 134271-93-5
• Molecular Weight: 193.205
• Mol File: 134271-93-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-(3-nitrophenyl)-2-propylidenehydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-nitrophenyl)-2-propylidenehydrazine(134271-93-5)
• EPA Substance Registry System: 1-(3-nitrophenyl)-2-propylidenehydrazine(134271-93-5)

Safety Data

• Hazardous Substances Data: 134271-93-5(Hazardous Substances Data)

Usage

General Description

1-(3-nitrophenyl)-2-propylidenehydrazine is a chemical compound with the molecular formula C10H13N3O2. It is a hydrazine derivative with a nitrophenyl group and a propylidene group attached to a hydrazine moiety. 1-(3-nitrophenyl)-2-propylidenehydrazine is known for its potential use as a pharmaceutical intermediate and a building block for the synthesis of various organic compounds. It has been studied for its potential biological activities, including its potential as an anti-tuberculosis agent. However, due to its hydrazine moiety, it is important to handle this chemical with caution and follow proper safety guidelines when working with it in a laboratory setting.

Upstream product

• 123-38-6 propionaldehyde 
• 619-27-2 3-nitrophenylhydrazine 
• 51516-96-2 3-nitrophenylhydrazine hydrochloride 
• 99-09-2 3-nitro-aniline 

Downstream Products

• 133053-76-6 3-methyl-6-nitro-1H-indole 
• 134271-94-6 3-methyl-4-nitro-1H-indole 
• 873056-08-7 (2'-ethoxy-2-aminobiphenyl-4-yl)-carbamic acid tert-butyl ester 

Relevant articles and documents

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.